Simovic I, Castaño-Rodríguez N, Kaakoush NO. OPCML: A Promising Biomarker and Therapeutic Avenue.
Trends Cancer 2019;
5:463-466. [PMID:
31421903 DOI:
10.1016/j.trecan.2019.06.002]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 05/29/2019] [Accepted: 06/04/2019] [Indexed: 10/26/2022]
Abstract
Opioid-binding protein/cell adhesion molecule (OPCML) is expressed in many tissues and localizes to the plasma membrane. It is a putative tumor suppressor that acts on receptor tyrosine kinases (RTKs), influencing cell cycle arrest, apoptosis, and migration. Its expression is silenced epigenetically in cancer, inferring potential diagnostic, prognostic, and therapeutic roles.
Collapse